Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

  • Technology appraisal guidance
  • TA412
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1

Radium‑223 dichloride is recommended as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults, only if:

  • they have already had docetaxel or

  • docetaxel is contraindicated or is not suitable for them.

    The drug is only recommended if the company provides radium‑223 dichloride with the discount agreed in the patient access scheme.

1.2

This guidance is not intended to affect the position of patients whose treatment with radium‑223 dichloride was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.